Overview of results from the Vitamin D Assessment (ViDA) study.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

Who Took Part

The study group was 5110 adults.

By PubMed's age tags, the people studied were middle-aged adults, older adults and people over 80, both men and women.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Vitamin D, K2, Magnesium and Zinc study, the assignments were hidden from both participants and investigators until the end.

Some adults received a placebo instead of Vitamin D, K2, Magnesium and Zinc, giving a reference point.

Outcomes were monitored through routinely collected health data and self-completed questionnaires.

What Was Measured

PubMed files the paper under topics including Accidental Falls, Arteries, Bone Density, Cardiovascular Diseases, Cholecalciferol, Dietary Supplements and Fractures, Bone.

The authors tagged it with the keywords Cancer, Clinical trial and Vitamin D supplementation.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 5110 adults.

With several hundred people or more, it is a fairly large study for this kind of research.

Its findings take up roughly 3 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2019 (Journal of endocrinological investigation), a journal based in Italy.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.